MiNK Therapeutics (INKT) Announces Transition of Chief Scientific Officer

On October 15, 2024, MiNK Therapeutics (NASDAQ: INKT) acknowledged that Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant. This transition will be effective as of November 15, 2024. Dr. Van Dijk will continue to contribute his expertise in his new role, supporting the Company’s programs and collaborations.

You May Also Be Interested In

• McCormick board member to resign after CFO appointment at Best Buy
• Flowers Foods (FLO) files mixed shelf
• BiomX announces 1-for-10 reverse stock split effective Sept. 9